SCHEMBL7815068

SCHEMBL7815068

CCCn1[c]nc2cc(OC)ccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.47
ALDH1A1 P00352 7/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
DYRK1A Q13627 1/20 0.39
HTR6 P50406 1/20 0.39
FGFR1 P11362 2/20 0.39
KDM4E B2RXH2 4/20 0.39
GAA P10253 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
LMNA P02545 2/20 0.39
TSHR P16473 1/20 0.39
MAPT P10636 3/20 0.39
POLB P06746 3/20 0.38
HTT P42858 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
NQO2 P16083 1/20 0.38
ACSS2 Q9NR19 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7805184 0.89 TDP1 (0.51) TDP1ALDH1A1SMN1; SMN2HTR6FGFR1
SCHEMBL7804842 0.88 DYRK1A (0.42) TDP1ALDH1A1SMN1; SMN2DYRK1AKDM4E
SCHEMBL7810877 0.85 FGFR1 (0.49) ALDH1A1FGFR1MAPT
SCHEMBL7814439 0.82 TDP1 (0.41) TDP1ALDH1A1SMN1; SMN2FGFR1KDM4E
SCHEMBL3652546 0.80 TDP1 (0.44) TDP1ALDH1A1SMN1; SMN2FGFR1KDM4E
SCHEMBL11227007 0.80 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2HTR6FGFR1KDM4E
SCHEMBL7821616 0.76 TDP1 (0.44) TDP1ALDH1A1SMN1; SMN2DYRK1AKDM4E
SCHEMBL1828029 0.75 SLC9A1 (0.47) TDP1ALDH1A1SMN1; SMN2KDM4EGAA
SCHEMBL7811008 0.73 TDP1 (0.41) TDP1ALDH1A1SMN1; SMN2FGFR1KDM4E
SCHEMBL7815075 0.73 FGFR1 (0.43) ALDH1A1FGFR1ACSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0745600-B1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO CO (JP) 2001-10-24 EP disclosed
US-5886014-A TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS SANKYO COMPANY, LIMITED (JP) 1999-03-23 US disclosed
EP-0745600-A1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-12-04 EP disclosed